Results 11 to 20 of about 2,479 (207)

The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow

Cells, 2022
Monoclonal antibodies directed against the neuropeptide calcitonin gene-related peptide (CGRP) belong to a new generation of therapeutics that are effective in the prevention of migraine.
Mária Dux, Jennifer Stratton, Karl Messlinger   +2 more
exaly   +3 more sources

Efficacy and continuability of 675 mg fremanezumab administration over 2 years [PDF]

The Journal of Headache and Pain
Background Real-world data on the long-term adherence to- and efficacy of fremanezumab 675 mg quarterly dosing remain scarce. Our study evaluated the efficacy of- and patient adherence to 675 mg fremanezumab for episodic migraine (EM) and chronic ...
Shohei Yoshida, Noboru Imai, Masato Keicho, Jun Kamimura, Asami Moriya, Nobuyasu Yagi, Rieko Suzuki, Takashi Konishi, Masahiro Serizawa   +8 more
doaj   +2 more sources

Real-World Clinical Effectiveness and Migraine-Related Healthcare Resource Utilization in Patients Initiating Fremanezumab in Germany and the United Kingdom [PDF]

Therapeutics and Clinical Risk Management
Axel Heinze,1 Shazia K Afridi,2 Todor I Totev,3 Lynda J Krasenbaum,4 Emi Terasawa,5 Hasan Akcicek,6 Joachim Hipp,7 Dalbir Dhiraj,8 Rochelle Sun,3 Erica Yim,5 Binyam Yilma,5 Maurice T Driessen9 1Migraine and Headache Center, Pain Clinic Kiel, Kiel ...
Heinze A, Afridi SK, Totev TI, Krasenbaum LJ, Terasawa E, Akcicek H, Hipp J, Dhiraj D, Sun R, Yim E, Yilma B, Driessen MT   +11 more
doaj   +2 more sources

Two Cases of Ischemic Complications in Abdominoplasty After Use of a New Biologic Migraine Medication [PDF]

Plastic and Reconstructive Surgery, Global Open
Summary:. Abdominoplasty is a common aesthetic procedure, and ischemic complications are rare, particularly in nonsmokers. We present 2 cases of ischemic complications in nonsmoking patients treated with fremanezumab, a biologic medication for severe ...
Reetta Tuominen, MD, PhD, Virve Koljonen, MD, PhD   +1 more
doaj   +2 more sources

Impact of anti-CGRP monoclonal antibodies on treatment satisfaction and quality of life in patients with resistant migraine: a retrospective real-world study. [PDF]

BMC Neurol
Migraine disorders; Anti-CGRP monoclonal antibodies; Quality of lifeTrastorns de la migranya; Anticossos monoclonals anti-CGRP; Qualitat de vidaTrastornos migrañosos; Anticuerpos monoclonales anti-CGRP; Calidad de vidaBackground: Several studies have ...
Cardona-Roca L, Seguí-Solanes C, Cano-Alonso M, Sosa-Pons A, Almendros-Abad N, Sola NR.   +5 more
europepmc   +3 more sources

Fremanezumab

Medicus, 2021
Fremanezumab is a humanized, monoclonal IgG2 antibody directed against calcitonin gene-related peptide, developed for specific prophylactic therapy of migraines. The calcitonin gene-related peptide is a vasoactive neuropeptide involved in the nociception and pathogenesis of the migraine.
Luana Lionetto, Matilde Capi, Valerio De Angelis, Paolo Martelletti   +3 more
  +6 more sources

Physical activity as a predictor of fremanezumab response in chronic migraine – the Phy-Fre-Mig study [PDF]

The Journal of Headache and Pain
Background The relationship between physical activity (PA) and migraine is insufficiently understood. Studies have not analysed levels of PA or Time Sitting (TS) during preventive treatment, nor the role these might play in the response to preventive ...
Álvaro Sierra-Mencía, Andrea Recio-García, David García-Azorín, Antonio José Molina de la Torre, Isabel Ros González, Ángel Luis Guerrero-Peral   +5 more
doaj   +2 more sources

A Real-World Study of CGRP Monoclonal Antibodies for Migraine: Long-Term Effectiveness and Treatment Adherence. [PDF]

Eur J Neurol
In our 24‐month real‐world study, the mean monthly migraine days (MMDs) significantly decreased from baseline by 6.8, 7.9, 8.7, and 10.0 days at Months 3, 6, 12, and 24, respectively (all p < 0.001). Significant reductions were also observed across all time points in both episodic migraine and chronic migraine subgroups.
Suzuki K, Suzuki S, Kobayashi S, Shioda M, Fujita H, Haruyama Y, Hirata K.   +6 more
europepmc   +2 more sources

Reduced Frequency of Prolonged Sporadic Hemiplegic Migraine Attacks Following Fremanezumab Treatment-A Case Report. [PDF]

Eur J Neurol
A 64‐year‐old man was admitted to the stroke unit with acute aphasia and right‐sided hemiplegia, but imaging showed no signs of acute stroke. Symptoms gradually improved and fully resolved by Day 21, following the onset of a hemicranial headache. A diagnosis of sporadic hemiplegic migraine was made, and no further attacks occurred under fremanezumab ...
Hotz JF, Kaindl L, Krebs S, Vigl M, Ferrari J, Neumann C, Han R, Ritscher L, Sykora M, Gallmetzer P.   +9 more
europepmc   +2 more sources

Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study. [PDF]

, 2023
BACKGROUND The ongoing Pan-European Real Life (PEARL) phase 4 study is evaluating fremanezumab effectiveness and safety for the prevention of episodic and chronic migraine.
Ahn, Andrew H.,, Amin, Faisal Mohammad,, Ashina, Messoud,, Dorman, Paul J.,, Kokturk, Pinar,, Lund University., Lund University., Lund University., Lyras, Leonidas,, Martins, Isabel Pavão,, Mitsikostas, Dimos D.,, Nežádal, Tomáš,, Poole, Anne Christine,, Pozo-Rosich, Patricia,, Ramirez Campos, Verena,, Sahin, Gurdal,, Schankin, Christoph J.,, Sumelahti, Marja Liisa,, Tassorelli, Cristina,   +18 more
core   +5 more sources